Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Massion, Pierre P ^a   Zou, Yong ^a   Uner, Hasmet ^b   Kiatsimkul, Porntip ^b   Wolf, Holly J ^b   Baron, Anna E ^b   Byers, Tom ^b   Jonsson, Steinn ^c   Lam, Stephen ^d   Hirsch, Fred R ^b   Miller, York E ^a   Franklin, Willbur A ^b   Varella Garcia, Marileila ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF ICELAND   (Iceland)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MYC PROTEIN; PROTEIN P63; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRONCHUS BIOPSY; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; CENTROMERE; CHROMOSOME 3Q; CHROMOSOME 5P; CHROMOSOME 7P; CHROMOSOME 8Q; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DUPLICATION; GENE LOCUS; GENE NUMBER; GENE PROBE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC GAIN; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; BIOPSY; BRONCHOSCOPY; CASE CONTROL STUDY; GENETICS; GENOMICS; HUMAN GENOME; LUNG TUMOR; METABOLISM; MIDDLE AGED; PRECANCER; RISK;

ADULT; AGED; BIOPSY; BRONCHOSCOPY; CASE-CONTROL STUDIES; FEMALE; GENOME, HUMAN; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RISK; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 67649234449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005611     Document Type: Article

References (56)

1. Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, et al. (1996) Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 201: 798-802.
2. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. (2006) Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355: 1763-1771.
3. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, et al. (2007) Computed tomography screening and lung cancer outcomes. Jama 297: 953-961.
4. Mulshine JL, Sullivan DC (2005) Clinical practice. Lung cancer screening. N Engl J Med 352: 2714-2720.
5. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, et al. (2002) Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 20: 911-920.
6. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, et al. (2002) Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 165: 508-513.
7. Wardwell NR, Massion PP (2005) Novel strategies for the early detection and prevention of lung cancer. Semin Oncol 32: 259-268.
8. Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1: 49-52.
9. Testa JR, Siegfried JM, Liu Z, Hunt JD, Feder MM, et al. (1994) Cytogenetic analysis of 63 non-small cell lung carcinomas: recurrent chromosome alterations amid frequent and widespread genomic upheaval. Genes Chromosomes Cancer 11: 178-194.
10. Varella-Garcia M, Chen L, Powell RL, Hirsch FR, Kennedy TC, et al. (2007) Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer. Am J Respir Crit Care Med 176: 505-512.
11. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, et al. (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 97: 5462-5467.
12. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, et al. (2002) Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62: 3636-3640.
13. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, et al. (2003) Significance of p63 Amplification and Overexpression in Lung Cancer Development and Prognosis. Cancer Res 63: 7113-7121.
14. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
15. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, et al. (2005) Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570.
16. Salaun M, Sesboue R, Moreno-Swirc S, Metayer J, Bota S, et al. (2008) Molecular predictive factors for progression of high-grade preinvasive bronchial lesions. Am J Respir Crit Care Med 177: 880-886.
17. Varella-Garcia M (2003) Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy. Oncologist 8: 45-58.
18. Sokolova IA, Bubendorf L, O'Hare A, Legator MS, Jacobson KK, et al. (2002) A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer 96: 306-315.
19. Halling KC, Rickman OB, Kipp BR, Harwood AR, Doerr CH, et al. (2006) A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest 130: 694-701.
20. Bubendorf L, Muller P, Joos L, Grilli B, Vogel S, et al. (2005) Multitarget FISH analysis in the diagnosis of lung cancer. Am J Clin Pathol 123: 516-523.
21. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, et al. (2009) EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 4: 318-325.
22. Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, et al. (2008) Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 14: 6317-6323.
23. Jonsson S, Varella-Garcia M, Miller YE, Wolf HJ, Byers T, et al. (2008) Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Am J Respir Crit Care Med 177: 342-347.
24. Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, et al. (2007) Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer 56: 175-184.
25. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, et al. (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102: 9625-9630.
26. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
27. Nau MM, Brooks BJ Jr, Carney DN, Gazdar AF, Battey JF, et al. (1986) Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A 83: 1092-1096.
28. Gazdar AF, Shigematsu H, Herz J, Minna JD (2004) Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 10: 481-486.
29. Franklin W, Wistuba I, Geisinger K, Lam S, Hirsch F, et al. (2004) Squamous dysplasia and carcinoma in situ. In: Travis WDBE, Müller-Hermerlink, Harris CC, eds. Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press. pp 68-72.
30. Massion P, Gray J (2002) Molecular Cytogenetic Explorations of Human Genome. In: Galas SMaD, ed. Genomic Technologies: Present and Future Evolution of Genomic Technologies.
31. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
32. Gonen M (2007) Analyzing Receiver Operating Characteristic Curves with SAS. In: MG, ed. Cary, Nc: SAS Institute Inc. pp 37-51.
33. Rahman SM, Shyr Y, Yildiz PB, Gonzalez AL, Li H, et al. (2005) Proteomic patterns of preinvasive bronchial lesions. Am J Respir Crit Care Med 172: 1556-1562.
34. Auerbach O, Stout AP, Hammond EC, Grafinkel L (1961) Changes in bronchial epithelum in reaction to cigrarette smoking and in relation to lung cancer. N Engl J Med 265: 253-267.
35. Bota S, Auliac JB, Paris C, Metayer J, Sesboue R, et al. (2001) Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med 164: 1688-1693.
36. Albertson DG, Collins C, McCormick F, Gray JW (2003) Chromosome aberrations in solid tumors. Nat Genet 34: 369-376.
37. Ried T, Liyanage M, du Manoir S, Heselmeyer K, Auer G, et al. (1997) Tumor cytogenetics revisited: comparative genomic hybridization and spectral karyotyping. J Mol Med 75: 801-814.
38. Luk C, Tsao MS, Bayani J, Shepherd F, Squire JA (2001) Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 125: 87-99.
39. Ye CJ, Liu G, Bremer SW, Heng HH (2007) The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res 118: 237-246.
40. Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E, et al. (1997) Comparative genomic hybridization analysis detects frequent, often high- level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res 57: 2116-2120.
41. Lockwood WW, Chari R, Coe BP, Girard L, Macaulay C, et al. (2008) DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 27: 4615-4624.
42. Wistuba II (2007) Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med 7: 3-14.
43. Garnis C, Coe BP, Ishkanian A, Zhang L, Rosin MP, et al. (2004) Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. Genes Chromosomes Cancer 39: 93-98.
44. Garnis C, Buys TP, Lam WL (2004) Genetic alteration and gene expression modulation during cancer progression. Mol Cancer 3: 9.
45. Choi YW, Choi JS, Zheng LT, Lim YJ, Yoon HK, et al. (2007) Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung. Lung Cancer 55: 43-51.
46. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, et al. (2006) High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 118: 1556-1564.
47. Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, et al. (2007) Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A 104: 16663-16668.
48. Kim TM, Yim SH, Lee JS, Kwon MS, Ryu JW, et al. (2005) Genome-wide screening of genomic alterations and their clinicopathologic implications in nonsmall cell lung cancers. Clin Cancer Res 11: 8235-8242.
49. Yakut T, Schulten HJ, Demir A, Frank D, Danner B, et al. (2006) Assessment of molecular events in squamous and non-squamous cell lung carcinoma. Lung Cancer 54: 293-301.
50. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, et al. (2007) TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 6: 274-285.
51. Broers JL, Viallet J, Jensen SM, Pass H, Travis WD, et al. (1993) Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 9: 33-43.
52. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, et al. (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5: 1966-1975.
53. Bergh JC (1990) Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes. Am Rev Respir Dis 142: S20-26.
54. Prudkin L, Wistuba II (2006) Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann Diagn Pathol 10: 306-315.
55. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM (2008) Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet 182: 1-11.
56. Garnis C, Davies JJ, Buys TP, Tsao MS, MacAulay C, et al. (2005) Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene 24: 4806-4812.